Cardispan Sol INJECTION 5 AMPS 5ml
THIS IS THE BRAND MEDICATION FROM GROSSMAN
CARDISPAN® is indicated for the treatment of levocarnitine deficiency, which can be primary (cardiomyopathy, myopathy, inborn errors of metabolism and muscular dystrophy), or secondary, as well as those conditions where necessary to increase production body energy by utilizing long chain fatty acids as energy source. Secondary levocarnitine deficiency exists by:
(1) Lack of synthesis and / or contribution (artificial nutrition, malnutrition or poor eating habits, premature infants and underweight children, fed soy or casein formulas, strict vegetarianism, liver cirrhosis infants).
(2) High consumption of levocarnitine (acute and chronic myocardial ischemia: myocardial infarction, angina pectoris, congestive heart failure, arrhythmias, myocardiosclerosis, senile heart surgery CABG surgery, peripheral vascular disease and patients in rehabilitation or fitness ).
(3) Loss of levocarnitine (treated with renal failure or hemodialysis, hypercatabolic conditions such as sepsis, burns, major trauma and surgery, hyperthyroidism, pregnancy, secondary cardiomyopathies the use of tricyclic antidepressants, valproic acid or antineoplastic).
(4) metabolic and endocrine disorders (diabetes mellitus, diabetic ketoacidosis, hyperlipoproteinemia, endogenous obesity, hypothyroidism, hypopituitarism, Addison's disease and Cushing's syndrome).
Other uses: In sports medicine, levocarnitine is used as a nutritional supplement and ergogenic substance in healthy people who participate in sport activities. Because of its role in lipid metabolism, is used as an adjunct to the medical management of weight control in patients with exogenous obesity due to excessive food intake and disorderly.
CARDISPAN® contains levocarnitina, natural constituent of the human body. Only the levorotatory isomer is biologically active. It plays an essential role in metabolism for energy production. The intramitochondrial beta-oxidation of fatty acids, is the largest and most efficient source of energy (ATP) but is required to produce the essential transport, levocarnitine, physiological substance that generates power by transporting fatty acids from the cytosol to the mitochondrial matrix where performed with the beta-oxidation production of acetyl coenzyme A and ATP with the Krebs cycle, facilitates the metabolism of carbohydrates and remove toxic compounds from inside the mitochondria resulted AcoA accumulation. Therefore, levocarnitine is essential to provide the energy substrate, primarily in skeletal muscle and myocardium; deficiency brings about significant changes in lipid metabolism, made possible by a lower production of energy, for an accumulation of free fatty acids and triglycerides.
Ischemia and intense physical activity cause significant metabolic changes as there is an increase in the energy requirement. Under these conditions occurs a great loss and / or increased demand for metabolic levocarnitina lipid utilization, ketone bodies and amino acid chains.
In children, increased energy demands during growth, athletic demands, periods of fasting, fever, infections and convalescence.
In premature exists inactivity butyrobetaine hydroxylase enzyme necessary for the endogenous synthesis of carnitine, which results in alteration of the use of fatty acids, stunting and psychomotor progress.
Cardispan corrects carnitine deficiency pregnancy itself. Levocarnitine is necessary for adequate oxidation of fatty acids and thus a proper fetal development. It is also essential for the synthesis of sufractante factor (phosphatidylcholine) in fetuses, as it encourages the replacement of fatty acids from membrane phospholipids pneumocytes, which when administered at least from the second half of pregnancy may increase the efficiency of steroids in the preventive management of respiratory distress syndrome.
In type II diabetic patients, promotes fatty acid metabolism, accumulation in cytoplasm blocks expression type transporter 4 (GLUT4) insulin, so levocarnitine improves insulin sensitivity, promotes glucose utilization and reduces the accumulation free fatty acids.
In patients undergoing hemodialysis nephropathy large amounts of fatty acids that cause mitochondrial apoptosis, weakness and concentrated arrhythmias. The fatty acids also accumulated block potassium channels, favoring arrhythmias. Levocarnitine allows better management of fatty acids, decreasing insulin resistance, arrhythmias and weakness. In the nephropathy patients, levocarnitine increased erythrocyte osmotic resistance, increasing half-life and thus reducing the consumption of erythropoietin by at least 37 to 38%.
Levocarnitine naturally acquired by ingestion of food, especially of animal origin, and can be synthesized in the liver and kidneys from the amino acids lysine and methionine. Levocarnitine is absorbed in the small intestine, mainly in the jejunum. Enters the circulation and is widely distributed in the body. Its presence in tissues suggests the existence of a cellular system and selective uptake in skeletal muscle myocardium and liver and kidney. Most levocarnitine body is excreted in urine and feces.
The time to reach peak concentration is 3.3 hours for tablets and oral solution. The peak plasma concentration after oral dose is approximately 80 nanomoles per mL, the bioabilidad after ingesting 2 grams of oral dose is 15 to 16%. Like all normal substances in the body, there is a constant turnover or use of certain compound. It has been estimated that 83.5% of the levocarnitine is eliminated unchanged in the urine within 24 hours.
Hypersensitivity to levocarnitine.
PRECAUTIONS: Tablets should be chewed to be swallowed. The product has no toxicity even at doses as high as 15 g per day, as it is a substance that normally exists in the organism.
RESTRICTIONS OF USE DURING PREGNANCY AND BREASTFEEDING ANDRESTRICTIONS OF USE DURING PREGNANCY AND LACTATION:
There are no restrictions on use during pregnancy and lactation. In fact, the requirements are increased in such conditions. Levocarnitine is a normal component of breast milk.
ADVERSE REACTIONS :
Higher doses of 3 g per day are associated with softening the stool and in some cases, the presence of diarrhea without clinical significance. It has been reported fishy sweating in less than 2% of the population; this can be avoided by decreasing the dose.
DRUG INTERACTIONS : None reported to date.
CHANGES IN RESULTS OF LABORATORY TESTS: There have been reported to date.
RECOMMENDED STORAGE: Store at room temperature to no more than 30 ° C and dry temperature.
MANIFESTATIONS AND MANAGEMENT OF OVERDOSE OR ACCIDENTAL INGESTION: Not informed about the presence of cases of overdose with this product.
PRECAUTIONS IN RELATION TO EFFECTS Carcinogenesis, Mutagenesis, Impairment of Fertility: Studies have shown that levocarnitine is not mutagenic, teratogenic and has no effect on fertility. There have been studies on carcinogenesis, as levocarnitine is a natural constituent of the human.
- Drug Name: Cardispan
- Comparative Brand: Cardispan
- Active ingredient: LEVOCARNITA
- Packaging: INJ.
- Concentration: 5ML
- Response time: No
- Laboratory GROSMAN, SA de CV
- Box of 5 BULBS
- Manufactured in: Mexico
Please consult your physician before taking any medication.